This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Effects of telmisartan on the level of Aβ1-42, interleukin-1β, tumor necrosis factor α and cognition in hypertensive patients with Alzheimer’s disease


Li, Wei, Zhang, Jie-Wen, Lu, Fen, Ma, Ming-Ming, Wang, Jiang-qiao, Suo, Ai-Qin, Bai, Ying-ying, Liu, Hui-qin


Zhonghua Yi Xue Za Zhi, Volume: 92, No.: 39, Pages.: 2743-2746

Year of Publication



Objective: To explore the effects of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor γ-stimulating activity, on the levels of Aβ1-42, interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α) and cognition in elderly hypertensive patients with Alzheimer’s disease (AD).; Methods: A total of 48 patients with probable AD and essential hypertension were randomly assigned into telmisartan group (n = 24, 40 – 80 mg qd) or amlodipine group (n = 24, 5 – 10 mg qd) for 6 months at Henan Provincial People’s Hospital during 2008 – 2011. Cognitive evaluations were assessed at pre-treatment and 24 weeks post-treatment by clinical assessment, rating scales and neuropsychological tests while the cerebrospinal fluid (CSF) levels of Aβ1-42, IL-1β and TNF-α by enzyme-linked immunosorbent assay (ELISA).; Results: After 6 months, mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) significantly decreased compared with baseline values to a similar extent in both groups. No significant differences existed between two groups in SBP or DBP. The patients displayed significantly higher Aβ1-42 and greatly lower levels of IL-1β and TNF-α in the telmisartan group versus the amlodipine group (P < 0.05). At 24 weeks, the patients in the telmisartan group had better mini-mental state examination (MMSE) (22.0 ± 3.4) and Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) (15 ± 5) scales scores than those taking amlodipine (MMSE (19.5 ± 2.8) and ADAS-cog (18 ± 5). Patients treated with telmisartan had better improvement on the MMSE (P < 0.05) and ADAS-cog (P < 0.05) scales compared with the amlodipine group by the end of study week 24.; Conclusion: Telmisartan may delay the decreased level of Aβ1-42 and reduce the levels IL-1β and TNF-α in CSF so as to improve the cognitive function of elderly hypertensive patients with AD. With additional benefits in comparison with common antihypertensive drugs, it may offer a novel therapeutic strategy of AD.;


aged, aged, 80 and over, alzheimer disease, amlodipine, amyloid betapeptides, antihypertensive agents, benzimidazoles, benzoates, cerebrospinal fluid, cognition, complications, drug effects, drug therapy, female, humans, hypertension, interleukin1beta, male, metabolism, middle aged, peptide fragments, ppar gamma, psychology, telmisartan, therapeutic use, tumor necrosis factoralpha

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Non randomised controlled trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Akatinol, Other